Embecta Corp. (EMBC)

Market Cap	684.02M
Revenue (ttm)	1.08B
Net Income (ttm)	95.40M
Shares Out	58.51M
EPS (ttm)	1.62
PE Ratio	7.22
Forward PE	4.05
Dividend	$0.60 (5.13%)
Ex-Dividend Date	Dec 5, 2025

Volume	941,149
Open	11.53
Previous Close	11.53
Day's Range	11.50 - 11.89
52-Week Range	9.20 - 21.23
Beta	1.06
Analysts	Buy
Price Target	18.50 (+58.26%)
Earnings Date	Nov 25, 2025

About EMBC

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company’s products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient’s diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1924
• Employees: 1,850
• Stock Exchange: NASDAQ
• Ticker Symbol: EMBC
• Website: https://www.embecta.com

Financial Performance

In 2025, Embecta's revenue was $1.08 billion, a decrease of -3.80% compared to the previous year's $1.12 billion. Earnings were $95.40 million, an increase of 21.84%.

Analyst Summary

According to 2 analysts, the average rating for EMBC stock is "Buy." The 12-month stock price target is $18.5, which is an increase of 58.26% from the latest price.

Price Target

$18.5

(58.26% upside)

Analyst Consensus: Buy